Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESG206 in B-cell Lymphoid Malignancies
NCT05822843Phase 1Completed
- Sponsor
- Shanghai Escugen Biotechnology Co., Ltd.
- Start
- Aug 2023
- Primary completion
- Jan 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ESG206 in B-cell lymphoid malignancies (4 arms), sponsored by Shanghai Escugen Biotechnology Co., Ltd. Primary endpoint: Percentage of Participants Experiencing Any Treatment Emergent Adverse Events. Started Aug 2023; status: completed.
02
Drugs
ESG206
03
Conditions
B-cell lymphoid malignancies
Beyond the preview
Go deeper on NCT05822843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05822843.